共 152 条
[1]
Trompet S(2016)Non-response to (statin) therapy: the importance of distinguishing non-responders from non-adherers in pharmacogenetic studies Eur J Clin Pharmacol 72 431-437
[2]
Postmus I(2006)Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the cholesterol and pharmacogenetics (CAP) study Am J Cardiol 97 843-850
[3]
Slagboom PE(2016)Safety of Alirocumab (a PCSK9 monoclonal antibody) from 14 randomized trials Am J Cardiol 118 1805-1811
[4]
Heijmans BT(2016)Reductions in Atherogenic lipids and major cardiovascular events: a pooled analysis of 10 ODYSSEY trials comparing Alirocumab with control Circulation 134 1931-1943
[5]
Smit RA(2015)Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial J Clin Endocrinol Metab 100 3140-3148
[6]
Maier AB(2015)Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial Eur Heart J 36 1186-1194
[7]
Simon JA(2016)Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial Atherosclerosis 244 138-146
[8]
Lin F(2016)Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg/dl or higher Cardiovasc Drugs Ther 30 473-483
[9]
Hulley SB(2015)ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia Eur Heart J 36 2996-3003
[10]
Blanche PJ(2015)Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study Am Heart J 169 906-915